Holen Sie sich die Stockscreener-App
17.71
4.32%
-0.80
Vorhandelsmarkt:
17.70
-0.01
-0.06%
Arcturus Therapeutics Holdings Inc Aktie (ARCT) Neueste Nachrichten
Is Arcturus Therapeutics Holdings Inc. the Top Chart Pick This Week2025 Key Lessons & AI Driven Price Forecasts - kangso.co.kr
Arcturus Therapeutics Holdings Inc. Added to High Probability Setup ListWeekly Stock Summary & Accurate Technical Buy Alerts - beatles.ru
Arcturus Therapeutics Stock Rises After Promising Mid-Stage Data for OTC Deficiency Treatment - MSN
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q2 2025 Earnings Call Transcript - MSN
Is Now a Good Time to Reenter Arcturus Therapeutics Holdings Inc.July 2025 Breakouts & Safe Capital Allocation Plans - beatles.ru
Arcturus Therapeutics (ARCT) Surges 29% on Intraday Frenzy: What’s Fueling the Biotech Breakout? - AInvest
Intapp Posts Better-Than-Expected Earnings, Joins… - inkl
Arcturus Therapeutics (NASDAQ:ARCT) Upgraded at Wall Street Zen - MarketBeat
Arcturus Therapeutics Receives Bullish Rating Amid Promising Cystic Fibrosis and COVID-19 Vaccine Progress - AInvest
Citi Raises Arcturus Therapeutics Price Target to $49, Keeps Buy Rating - AInvest
William Blair Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating - 富途牛牛
Mercury Systems Surges 24.6% After Reporting Better-Than-Expected Q4 Earnings, Green Dot, Arcturus Therapeutics, and Other Stocks Rise Amid US Market Gains - AInvest
Mercury Systems Posts Better-Than-Expected Earnings,… - inkl
Arcturus Therapeutics shares rise 29.68% intraday after positive interim Phase 2 data for ARCT-810. - AInvest
Real Messenger Corporation shares rise 28.05% intraday after Arcturus Therapeutics announced positive Phase 2 data for ARCT-810. - AInvest
Arcturus Therapeutics: Wells Fargo Maintains Overweight, PT Down to $42 from $45 - AInvest
Wells Fargo lowers Arcturus Therapeutics stock price target to $42 on model updates - Investing.com Canada
Arcturus Therapeutics shares rise 6.23% premarket after positive interim Phase 2 data for ARCT-810. - AInvest
Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress - BioSpace
Arcturus Therapeutics Reports Q2 2025 Earnings and Pipeline Progress - TipRanks
Arcturus Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Arcturus Therapeutics Holdings Inc earnings missed by $3.55, revenue fell short of estimates - Investing.com Nigeria
Arcturus Therapeutics Advances CF and OTC Programs, Plans Regulatory Meetings in 2026 - AInvest
Transcript : Arcturus Therapeutics Holdings Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
Arcturus Tightens Its Belt As Analysts Stay Bullish - Finimize
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Arcturus Therapeutics: Q2 Earnings Snapshot - MarketScreener
Earnings call transcript: Arcturus Therapeutics Q2 2025 results miss expectations - Investing.com
Arcturus Therapeutics Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Arcturus Therapeutics Q2 net loss narrows - MarketScreener
Arcturus Therapeutics shares edge higher despite earnings miss in Q2 - Investing.com India
Arcturus Therapeutics shares edge higher despite earnings miss in Q2 By Investing.com - Investing.com Australia
Arcturus Therapeutics Q2 2025 Financial Update - TradingView
Short interest data insights for Arcturus Therapeutics Holdings Inc.Historical Market Behavior and Trend Summary - Newser
Risk vs reward if holding onto Arcturus Therapeutics Holdings Inc.Swing Trade Timing with Daily Forecast - Newser
Multi factor analysis applied to Arcturus Therapeutics Holdings Inc.High Yield Signals with Entry Timing - Newser
Arcturus Therapeutics Q2 2025 Earnings Preview: Analysts Expect EPS of -$0.87, Revenue of $18.71M. - AInvest
Arcturus Therapeutics Holdings Inc expected to post a loss of 89 cents a shareEarnings Preview - TradingView
What To Expect From Arcturus Therapeutics Holdings Inc (ARCT) Q2 2025 Earnings - GuruFocus
Lipid Nanoparticles Market Industry Trends, Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2034 - GlobeNewswire Inc.
Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Is Arcturus Therapeutics Holdings Inc. stock overvalued or undervaluedHigh-yield portfolio picks - Jammu Links News
What is the risk reward ratio of investing in Arcturus Therapeutics Holdings Inc. stockRapid return acceleration - Jammu Links News
How does Arcturus Therapeutics Holdings Inc. compare to its industry peersFree Risk Assessment Services - Jammu Links News
What are analysts’ price targets for Arcturus Therapeutics Holdings Inc. in the next 12 monthsBuild a winning investment portfolio - Jammu Links News
When is Arcturus Therapeutics Holdings Inc. stock expected to show significant growthDiscover breakthrough stocks before the crowd - Jammu Links News
Is Arcturus Therapeutics Holdings Inc. a growth stock or a value stockGet professional guidance for market timing - Jammu Links News
What catalysts could drive Arcturus Therapeutics Holdings Inc. stock higher in 2025Get alerts on high-potential stock breakouts - Jammu Links News
What drives Arcturus Therapeutics Holdings Inc. stock priceAchieve rapid financial growth with smart picks - Jammu Links News
What is Arcturus Therapeutics Holdings Inc. company’s growth strategyTremendous financial leverage - Jammu Links News
What are Arcturus Therapeutics Holdings Inc. company’s key revenue driversRapid return acceleration - Jammu Links News
1.38%
0.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):